{"pmid":32424603,"title":"COVID-19 in adults: test menu for hospital blood science laboratories.","text":["COVID-19 in adults: test menu for hospital blood science laboratories.","INTRODUCTION: Coronavirus disease 2019 (COVID-19), is a respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Clinical Blood Sciences Laboratory (CBSL) plays a key role in supporting the monitoring and management of patients with COVID-19 disease. OBJECTIVE: To provide a comprehensive CBSL testing protocol to support the medical management of SARS-CoV-2 infection. METHODS: Description of the biochemical, haematological and immunological tests that have a role in the assessment and monitoring of patients with COVID-19 infection. RESULTS: We provide a test menu for clinical laboratories to ensure the effective monitoring, management and prognostication of COVID-19 patients in hospital. CONCLUSION: Given the rapidity with which patients with COVID-19 disease can deteriorate, we recommend regular testing with vigilance paid to the rate and trajectory of change in each of these parameters.","Ir J Med Sci","O'Shea, Paula M","Lee, Graham Robert","Griffin, Tomas P","Tormey, Vincent","Hayat, Amjad","Costelloe, Sean J","Griffin, Damian Gerard","Srinivasan, Saradha","O'Kane, Maurice","Burke, Conor M","Faul, John","Thompson, Christopher J","Curley, Gerard","Tormey, William P","32424603"],"abstract":["INTRODUCTION: Coronavirus disease 2019 (COVID-19), is a respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Clinical Blood Sciences Laboratory (CBSL) plays a key role in supporting the monitoring and management of patients with COVID-19 disease. OBJECTIVE: To provide a comprehensive CBSL testing protocol to support the medical management of SARS-CoV-2 infection. METHODS: Description of the biochemical, haematological and immunological tests that have a role in the assessment and monitoring of patients with COVID-19 infection. RESULTS: We provide a test menu for clinical laboratories to ensure the effective monitoring, management and prognostication of COVID-19 patients in hospital. CONCLUSION: Given the rapidity with which patients with COVID-19 disease can deteriorate, we recommend regular testing with vigilance paid to the rate and trajectory of change in each of these parameters."],"journal":"Ir J Med Sci","authors":["O'Shea, Paula M","Lee, Graham Robert","Griffin, Tomas P","Tormey, Vincent","Hayat, Amjad","Costelloe, Sean J","Griffin, Damian Gerard","Srinivasan, Saradha","O'Kane, Maurice","Burke, Conor M","Faul, John","Thompson, Christopher J","Curley, Gerard","Tormey, William P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424603","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11845-020-02252-0","keywords":["blood science testing","covid-19","hospital laboratories","monitoring and management"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728771231744,"score":9.490897,"similar":[{"pmid":32459192,"title":"Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","text":["Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.","Clin Chem Lab Med","Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow","32459192"],"abstract":["The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis."],"journal":"Clin Chem Lab Med","authors":["Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459192","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1515/cclm-2020-0722","keywords":["covid-19","sars-cov-2","biochemical monitoring","molecular testing","serology testing"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698909265920,"score":147.3445},{"pmid":32443899,"title":"Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy.","text":["Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy.","We described features of hospitalized Covid-19 patients and identified predictors of clinical deterioration. We included patients consecutively admitted at Humanitas Research Hospital (Rozzano, Milan, Italy); retrospectively extracted demographic; clinical; laboratory and imaging findings at admission; used survival methods to identify factors associated with clinical deterioration (defined as intensive care unit (ICU) transfer or death), and developed a prognostic index. Overall; we analyzed 239 patients (29.3% females) with a mean age of 63.9 (standard deviation [SD]; 14.0) years. Clinical deterioration occurred in 70 patients (29.3%), including 41 (17.2%) ICU transfers and 36 (15.1%) deaths. The most common symptoms and signs at admission were cough (77.8%) and elevated respiratory rate (34.1%), while 66.5% of patients had at least one coexisting medical condition. Imaging frequently revealed ground-glass opacity (68.9%) and consolidation (23.8%). Age; increased respiratory rate; abnormal blood gas parameters and imaging findings; coexisting coronary heart disease; leukocytosis; lymphocytopenia; and several laboratory parameters (elevated procalcitonin; interleukin-6; serum ferritin; C-reactive protein; aspartate aminotransferase; lactate dehydrogenase; creatinine; fibrinogen; troponin-I; and D-dimer) were significant predictors of clinical deterioration. We suggested a prognostic index to assist risk-stratification (C-statistic; 0.845; 95% CI; 0.8020.887). These results could aid early identification and management of patients at risk, who should therefore receive additional monitoring and aggressive supportive care.","J Clin Med","Cecconi, Maurizio","Piovani, Daniele","Brunetta, Enrico","Aghemo, Alessio","Greco, Massimiliano","Ciccarelli, Michele","Angelini, Claudio","Voza, Antonio","Omodei, Paolo","Vespa, Edoardo","Pugliese, Nicola","Parigi, Tommaso Lorenzo","Folci, Marco","Danese, Silvio","Bonovas, Stefanos","32443899"],"abstract":["We described features of hospitalized Covid-19 patients and identified predictors of clinical deterioration. We included patients consecutively admitted at Humanitas Research Hospital (Rozzano, Milan, Italy); retrospectively extracted demographic; clinical; laboratory and imaging findings at admission; used survival methods to identify factors associated with clinical deterioration (defined as intensive care unit (ICU) transfer or death), and developed a prognostic index. Overall; we analyzed 239 patients (29.3% females) with a mean age of 63.9 (standard deviation [SD]; 14.0) years. Clinical deterioration occurred in 70 patients (29.3%), including 41 (17.2%) ICU transfers and 36 (15.1%) deaths. The most common symptoms and signs at admission were cough (77.8%) and elevated respiratory rate (34.1%), while 66.5% of patients had at least one coexisting medical condition. Imaging frequently revealed ground-glass opacity (68.9%) and consolidation (23.8%). Age; increased respiratory rate; abnormal blood gas parameters and imaging findings; coexisting coronary heart disease; leukocytosis; lymphocytopenia; and several laboratory parameters (elevated procalcitonin; interleukin-6; serum ferritin; C-reactive protein; aspartate aminotransferase; lactate dehydrogenase; creatinine; fibrinogen; troponin-I; and D-dimer) were significant predictors of clinical deterioration. We suggested a prognostic index to assist risk-stratification (C-statistic; 0.845; 95% CI; 0.8020.887). These results could aid early identification and management of patients at risk, who should therefore receive additional monitoring and aggressive supportive care."],"journal":"J Clin Med","authors":["Cecconi, Maurizio","Piovani, Daniele","Brunetta, Enrico","Aghemo, Alessio","Greco, Massimiliano","Ciccarelli, Michele","Angelini, Claudio","Voza, Antonio","Omodei, Paolo","Vespa, Edoardo","Pugliese, Nicola","Parigi, Tommaso Lorenzo","Folci, Marco","Danese, Silvio","Bonovas, Stefanos"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32443899","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/jcm9051548","keywords":["2019 novel coronavirus","2019-ncov","covid-19","sars-cov-2","severe acute respiratory syndrome coronavirus 2"],"locations":["Rozzano","Milan","Italy","lymphocytopenia","Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Creatinine"],"topics":["Diagnosis"],"weight":1,"_version_":1667600475953823744,"score":135.9242},{"pmid":32356642,"title":"Can we predict the severity of COVID-19 with a routine blood test?","text":["Can we predict the severity of COVID-19 with a routine blood test?","INTRODUCTION: The ongoing worldwide pandemic of Coronavirus Disease 2019 (COVID-19) has posed a huge threat to global public health. However, whether routine blood test could be used to monitor and predict the severity and prognosis of COVID-19 has never been comprehensively investigated. OBJECTIVES: To provide an overview of the association of markers in routine blood test with the severity of COVID-19. METHODS: PubMed, Embase, Cochrane Library, Wanfang and CNKI database were searched to identify studies reporting the markers in the routine blood test with the severity of COVID-19 until March 20, 2020. STATA software was used for the meta- analysis. RESULTS: A total of 15 studies with 3090 COVID-19 patients were included in this analysis. Patients in non-severe group had fewer white blood cells (WBC) (WMD = -0.85 [109/L], 95% CI = [-1.54, -0.16], P = 0.02) and neutrophils (WMD = -1.57 [109/L], 95% CI = [-2.60, -0.54], P = 0.003), more lymphocytes (WMD = 0.29 [109/L], 95% CI = [0.22, 0.36], P < 0.001) and platelets (WMD = 19.05 [109/L], 95% CI = [3.04, 35.06], P = 0.02), and lower neutrophil-to-lymphocyte ratio (NLR) level (WMD = -2.48, 95% CI = [-3.81, -1.15], P < 0.001), compared with those in severe group. There was no statistical difference in monocytes (WMD = 0.01 [109/L], 95% CI = [-0.01, 0.03], P = 0.029) between these two groups. Sensitivity analysis and meta-analysis based on standard mean difference (SMD) did not change the conclusions about neutrophils, lymphocytes and NLR while the results were inconsistent in WBC and platelets. CONCLUSIONS: Severe patients had more neutrophils, higher NLR level, and fewer lymphocytes than non-severe patients with COVID-19. Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19.","Pol Arch Intern Med","Zeng, Furong","Li, Linfeng","Zeng, Jiling","Deng, Yuhao","Huang, Huining","Chen, Bin","Deng, Guangtong","32356642"],"abstract":["INTRODUCTION: The ongoing worldwide pandemic of Coronavirus Disease 2019 (COVID-19) has posed a huge threat to global public health. However, whether routine blood test could be used to monitor and predict the severity and prognosis of COVID-19 has never been comprehensively investigated. OBJECTIVES: To provide an overview of the association of markers in routine blood test with the severity of COVID-19. METHODS: PubMed, Embase, Cochrane Library, Wanfang and CNKI database were searched to identify studies reporting the markers in the routine blood test with the severity of COVID-19 until March 20, 2020. STATA software was used for the meta- analysis. RESULTS: A total of 15 studies with 3090 COVID-19 patients were included in this analysis. Patients in non-severe group had fewer white blood cells (WBC) (WMD = -0.85 [109/L], 95% CI = [-1.54, -0.16], P = 0.02) and neutrophils (WMD = -1.57 [109/L], 95% CI = [-2.60, -0.54], P = 0.003), more lymphocytes (WMD = 0.29 [109/L], 95% CI = [0.22, 0.36], P < 0.001) and platelets (WMD = 19.05 [109/L], 95% CI = [3.04, 35.06], P = 0.02), and lower neutrophil-to-lymphocyte ratio (NLR) level (WMD = -2.48, 95% CI = [-3.81, -1.15], P < 0.001), compared with those in severe group. There was no statistical difference in monocytes (WMD = 0.01 [109/L], 95% CI = [-0.01, 0.03], P = 0.029) between these two groups. Sensitivity analysis and meta-analysis based on standard mean difference (SMD) did not change the conclusions about neutrophils, lymphocytes and NLR while the results were inconsistent in WBC and platelets. CONCLUSIONS: Severe patients had more neutrophils, higher NLR level, and fewer lymphocytes than non-severe patients with COVID-19. Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19."],"journal":"Pol Arch Intern Med","authors":["Zeng, Furong","Li, Linfeng","Zeng, Jiling","Deng, Yuhao","Huang, Huining","Chen, Bin","Deng, Guangtong"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356642","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.20452/pamw.15331","locations":["Wanfang","monocytes"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495253479425,"score":123.26446},{"pmid":32344319,"pmcid":"PMC7175872","title":"Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples.","text":["Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples.","BACKGROUND: A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in late 2019 and subsequently caused a pandemic. Surveillance is important to better appreciate this evolving pandemic and to longitudinally monitor the effectiveness of public health measures. OBJECTIVES: We aimed to provide a rapid, easy to establish and costeffective laboratory-based surveillance tool for SARS-CoV-2. STUDY DESIGN: We used minipools of RNA prepared from nucleic acid extractions of routine respiratory samples. We technically validated the assay and distributed the protocol within an informal network of five German university laboratories. RESULTS: We tested a total of 70 minipools resembling 700 samples shortly before the upsurge of cases in Germany from 17.02.2020 to 10.03.2020. One minipool reacted positive and after resolution one individual sample tested SARS-CoV-2 positive. This sample was from a hospitalized patient not suspected of having contracted SARS-CoV-2. CONCLUSIONS: Our approach of a laboratory-based surveillance for SARSCoV-2 using minipools proved its concept is easily adaptable and resource-saving. It might assist not only public health laboratories in SARS-CoV-2 surveillance.","J Clin Virol","Eis-Hubinger, Anna M","Honemann, Mario","Wenzel, Jurgen J","Berger, Annemarie","Widera, Marek","Schmidt, Barbara","Aldabbagh, Souhaib","Marx, Benjamin","Streeck, Hendrik","Ciesek, Sandra","Liebert, Uwe G","Huzly, Daniela","Hengel, Hartmut","Panning, Marcus","32344319"],"abstract":["BACKGROUND: A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in late 2019 and subsequently caused a pandemic. Surveillance is important to better appreciate this evolving pandemic and to longitudinally monitor the effectiveness of public health measures. OBJECTIVES: We aimed to provide a rapid, easy to establish and costeffective laboratory-based surveillance tool for SARS-CoV-2. STUDY DESIGN: We used minipools of RNA prepared from nucleic acid extractions of routine respiratory samples. We technically validated the assay and distributed the protocol within an informal network of five German university laboratories. RESULTS: We tested a total of 70 minipools resembling 700 samples shortly before the upsurge of cases in Germany from 17.02.2020 to 10.03.2020. One minipool reacted positive and after resolution one individual sample tested SARS-CoV-2 positive. This sample was from a hospitalized patient not suspected of having contracted SARS-CoV-2. CONCLUSIONS: Our approach of a laboratory-based surveillance for SARSCoV-2 using minipools proved its concept is easily adaptable and resource-saving. It might assist not only public health laboratories in SARS-CoV-2 surveillance."],"journal":"J Clin Virol","authors":["Eis-Hubinger, Anna M","Honemann, Mario","Wenzel, Jurgen J","Berger, Annemarie","Widera, Marek","Schmidt, Barbara","Aldabbagh, Souhaib","Marx, Benjamin","Streeck, Hendrik","Ciesek, Sandra","Liebert, Uwe G","Huzly, Daniela","Hengel, Hartmut","Panning, Marcus"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344319","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jcv.2020.104381","keywords":["laboratory","minipools","rt-pcr","sars-cov-2","surveillance"],"locations":["China","German","Germany"],"countries":["Germany","China"],"countries_codes":["DEU|Germany","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495866896386,"score":122.29461},{"pmid":32385976,"title":"Diagnostic role of chest computed tomography in coronavirus disease 2019.","text":["Diagnostic role of chest computed tomography in coronavirus disease 2019.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that appeared in China in December 2019 and spread globally, evolving into the currently observed pandemic. The laboratory diagnosis of SARS-CoV-2 infection is currently based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR) testing, and imaging cannot replace genetic testing in patients suspected of COVID-19. However, with predominant respiratory manifestations of COVID-19, particularly in more severe cases, chest imaging using computed tomography (CT) plays a major role in detecting viral lung infection, evaluating the nature and extent of pulmonary lesions, and monitoring the disease activity. The role of chest CT as a diagnostic tool may be increased when the laboratory testing capacities using RT-PCR prove inaccurate or insufficient during a major outbreak of the disease. In these settings, a rapid presumptive diagnosis of COVID-19 potentially offered by CT might be an advantage, in addition to obvious benefits of delineating the nature and extent of pulmonary changes. In the present paper, we reviewed the diagnostic role of chest CT in COVID-19 patients.","Pol Arch Intern Med","Jedrusik, Piotr","Gaciong, Zbigniew","Sklinda, Katarzyna","Sierpinski, Radoslaw","Walecki, Jerzy","Gujski, Mariusz","32385976"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that appeared in China in December 2019 and spread globally, evolving into the currently observed pandemic. The laboratory diagnosis of SARS-CoV-2 infection is currently based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR) testing, and imaging cannot replace genetic testing in patients suspected of COVID-19. However, with predominant respiratory manifestations of COVID-19, particularly in more severe cases, chest imaging using computed tomography (CT) plays a major role in detecting viral lung infection, evaluating the nature and extent of pulmonary lesions, and monitoring the disease activity. The role of chest CT as a diagnostic tool may be increased when the laboratory testing capacities using RT-PCR prove inaccurate or insufficient during a major outbreak of the disease. In these settings, a rapid presumptive diagnosis of COVID-19 potentially offered by CT might be an advantage, in addition to obvious benefits of delineating the nature and extent of pulmonary changes. In the present paper, we reviewed the diagnostic role of chest CT in COVID-19 patients."],"journal":"Pol Arch Intern Med","authors":["Jedrusik, Piotr","Gaciong, Zbigniew","Sklinda, Katarzyna","Sierpinski, Radoslaw","Walecki, Jerzy","Gujski, Mariusz"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385976","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.20452/pamw.15348","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666340101966266368,"score":118.67971}]}